|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen ZM, Peto R, Iona A, Guo Y, Chen YP,
Bian Z, Yang L, Zhang WY, Lu F, Chen JS, et al: Emerging
tobacco-related cancer risks in China: A nationwide, prospective
study of 0.5 million adults. Cancer 121 Suppl. 17:3097–3106. 2015.
View Article : Google Scholar
|
|
3
|
Wood DE, Kazerooni E, Baum SL, Dransfield
MT, Eapen GA, Ettinger DS, Hou L, Jackman DM, Klippenstein D, Kumar
R, et al: Lung cancer screening, version 1.2015: Featured updates
to the NCCN guidelines. J Natl Compr Canc Netw. 13:23–34.
2015.PubMed/NCBI
|
|
4
|
Chang A: Chemotherapy, chemoresistance and
the changing treatment landscape for NSCLC. Lung Cancer. 71:3–10.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bowden NA: Nucleotide excision repair: Why
is it not used to predict response to platinum-based chemotherapy.
Cancer Lett. 346:163–171. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yamagishi T, Sahni S, Sharp DM, Arvind A,
Jansson PJ and Richardson DR: P-glycoprotein mediates drug
resistance via a novel mechanism involving lysosomal sequestration.
J Biol Chem. 288:31761–31771. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Selivanova G: Wild type p53 reactivation:
From lab bench to clinic. FEBS Lett. 588:2628–2638. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Triller N, Korosec P, Kern I, Kosnik M and
Debeljak A: Multidrug resistance in small cell lung cancer:
Expression of P-glycoprotein, multidrug resistance protein 1 and
lung resistance protein in chemo-naive patients and in relapsed
disease. Lung Cancer. 54:235–240. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Podolski-Renić A, Jadranin M, Stanković T,
Banković J, Stojković S, Chiourea M, Aljančić I, Vajs V, Tešević V,
Ruždijić S, et al: Molecular and cytogenetic changes in multi-drug
resistant cancer cells and their influence on new compounds
testing. Cancer Chemother Pharmacol. 72:683–697. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chung SK, Zhu S, Xu Y and Fu X: Functional
analysis of the acetylation of human p53 in DNA damage responses.
Protein Cell. 5:544–551. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chakraborty S, Mazumdar M, Mukherjee S,
Bhattacharjee P, Adhikary A, Manna A, Chakraborty S, Khan P, Sen A
and Das T: Restoration of p53/miR-34a regulatory axis decreases
survival advantage and ensures Bax-dependent apoptosis of non-small
cell lung carcinoma cells. FEBS Lett. 588:549–559. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jiang YL, Meng N, Wang JJ, Jiang P, Yuan
HSh, Liu C, Qu A and Yang RJ: CT-guided iodine-125 seed permanent
implantation for recurrent head and neck cancers. Radiat Oncol.
5:682010.PubMed/NCBI
|
|
13
|
Schroeder T, Kuendgen A, Kayser S, Kröger
N, Braulke F, Platzbecker U, Klärner V, Zohren F, Haase D, Stadler
M, et al: Therapy-related myeloid neoplasms following treatment
with radioiodine. Haematologica. 97:206–212. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yi T, Yi Z, Cho SG, Luo J, Pandey MK,
Aggarwal BB and Liu M: Gambogic acid inhibits angiogenesis and
prostate tumor growth by suppressing vascular endothelial growth
factor receptor 2 signaling. Cancer Res. 68:1843–1850. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gu H, You Q, Liu W, Yang Y, Zhao L, Qi Q,
Zhao J, Wang J, Lu N, Ling H, et al: Gambogic acid induced tumor
cell apoptosis by T lymphocyte activation in H22 transplanted mice.
Int Immunopharmacol. 8:1493–1502. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang LH, Li Y, Yang SN, Wang FY, Hou Y,
Cui W, Chen K, Cao Q, Wang S, Zhang TY, et al: Gambogic acid
synergistically potentiates cisplatin-induced apoptosis in
non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1
signalling. Br J Cancer. 110:341–352. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li C, Qi Q, Lu N, Dai Q, Li F, Wang X, You
Q and Guo Q: Gambogic acid promotes apoptosis and resistance to
metastatic potential in MDA-MB-231 human breast carcinoma cells.
Biochem Cell Biol. 90:718–730. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Qin Y, Meng L, Hu C, Duan W, Zuo Z, Lin L,
Zhang X and Ding J: Gambogic acid inhibits the catalytic activity
of human topoisomerase IIalpha by binding to its ATPase domain. Mol
Cancer Ther. 6:2429–2440. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li D, Yang H, Li R, Wang Y, Wang W, Li D,
Ma S and Zhang X: Antitumor activity of gambogic acid on NCI-H1993
xenografts via MET signaling pathway downregulation. Oncol Lett.
10:2802–2806. 2015.PubMed/NCBI
|
|
20
|
Wen C, Huang L, Chen J, Lin M, Li W, Lu B,
Rutnam ZJ, Iwamoto A, Wang Z, Yang X and Liu H: Gambogic acid
inhibits growth, induces apoptosis, and overcomes drug resistance
in human colorectal cancer cells. Int J Oncol. 47:1663–1671.
2015.PubMed/NCBI
|
|
21
|
Jang JH, Kim JY, Sung EG, Kim EA and Lee
TJ: Gambogic acid induces apoptosis and sensitizes TRAIL-mediated
apoptosis through downregulation of cFLIPL in renal carcinoma Caki
cells. Int J Oncol. 48:376–384. 2016.PubMed/NCBI
|
|
22
|
Wang X, Deng R, Lu Y, Xu Q, Yan M, Ye D
and Chen W: Gambogic acid as a non-competitive inhibitor of
ATP-binding cassette transporter B1 reverses the multidrug
resistance of human epithelial cancers by promoting ATP-binding
cassette transporter B1 protein degradation. Basic Clin Pharmacol
Toxicol. 112:25–33. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wellman PJ, Tow S and McMahon L:
Isobolographic assessment of the effects of combinations of
phenylpropanolamine and fenfluramine on food intake in rats.
Pharmacol Biochem Behav. 50:287–291. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gessner PK: Isobolographic analysis of
interactions: An update on applications and utility. Toxicology.
105:161–179. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chiou JF, Liang JA, Hsu WH, Wang JJ, Ho ST
and Kao A: Comparing the relationship of Taxol-based chemotherapy
response with P-glycoprotein and lung resistance-related protein
expression in non-small cell lung cancer. Lung. 181:267–273. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Oliver TG, Mercer KL, Sayles LC, Burke JR,
Mendus D, Lovejoy KS, Cheng MH, Subramanian A, Mu D, Powers S, et
al: Chronic cisplatin treatment promotes enhanced damage repair and
tumor progression in a mouse model of lung cancer. Genes Dev.
24:837–852. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cetintas VB, Kucukaslan AS, Kosova B,
Tetik A, Selvi N, Cok G, Gunduz C and Eroglu Z: Cisplatin
resistance induced by decreased apoptotic activity in
non-small-cell lung cancer cell lines. Cell Biol Int. 36:261–265.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kroger LA, DeNardo GL, Gumerlock PH, Xiong
CY, Winthrop MD, Shi XB, Mack PC, Leshchinsky T and DeNardo SJ:
Apoptosis-related gene and protein expression in human lymphoma
xenografts (Raji) after low dose rate radiation using
67Cu-2IT-BAT-Lym-1 radioimmunotherapy. Cancer Biother Radiopharm.
16:213–225. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kemény-Beke A, Berényi E, Facskó A,
Damjanovich J, Horváth A, Bodnár A, Berta A and Aradi J:
Antiproliferative effect of 4-thiouridylate on OCM-1 uveal melanoma
cells. Eur J Ophthalmol. 16:680–685. 2006.PubMed/NCBI
|
|
30
|
Szostak MJ, Kaur P, Amin P, Jacobs SC and
Kyprianou N: Apoptosis and bcl-2 expression in prostate cancer:
Significance in clinical outcome after brachytherapy. J Urol.
165:2126–2130. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Oka K, Suzuki Y, Iida H and Nakano T:
Radiation therapy induces the p53 (+) p21 (−) expression in
squamous cell carcinomas of the uterine cervix. Gynecol Oncol.
93:340–344. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Brantley MA Jr, Worley L and Harbour JW:
Altered expression of Rb and p53 in uveal melanomas following
plaque radiotherapy. Am J Ophthalmol. 133:242–248. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Harima Y, Nagata K, Harima K, Oka A,
Ostapenko VV, Shikata N, Ohnishi T and Tanaka Y: Bax and Bcl-2
protein expression following radiation therapy versus radiation
plus thermoradiotherapy in stage IIIB cervical carcinoma. Cancer.
88:132–138. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Nakada K, Ishibashi T, Takei T, Hirata K,
Shinohara K, Katoh S, Zhao S, Tamaki N, Noguchi Y and Noguchi S:
Does lemon candy decrease salivary gland damage after radioiodine
therapy for thyroid cancer? J Nucl Med. 46:261–266. 2005.PubMed/NCBI
|
|
35
|
Fallahi B, Adabi K, Majidi M,
Fard-Esfahani A, Heshmat R, Larijani B and Haghpanah V: Incidence
of second primary malignancies during a long-term surveillance of
patients with differentiated thyroid carcinoma in relation to
radioiodine treatment. Clin Nucl Med. 36:277–282. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Iyer NG, Morris LG, Tuttle RM, Shaha AR
and Ganly I: Rising incidence of second cancers in patients with
low-risk (T1N0) thyroid cancer who receive radioactive iodine
therapy. Cancer. 117:4439–4446. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li Q, Cheng H, Zhu G, Yang L, Zhou A, Wang
X, Fang N, Xia L, Su J, Wang M, et al: Gambogenic acid inhibits
proliferation of A549 cells through apoptosis-inducing and cell
cycle arresting. Biol Pharm Bull. 33:415–420. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Qi Q, Lu N, Li C, Zhao J, Liu W, You Q and
Guo Q: Involvement of RECK in gambogic acid induced anti-invasive
effect in A549 human lung carcinoma cells. Mol Carcinog. 54:(Suppl
1). E13–E25. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhu X, Zhang H, Lin Y, Chen P, Min J, Wang
Z, Xiao W and Chen B: Mechanisms of gambogic acid-induced apoptosis
in non-small cell lung cancer cells in relation to transferrin
receptors. J Chemother. 21:666–672. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wu ZQ, Guo QL, You QD, Zhao L and Gu HY:
Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1
cells in vivo and in vitro and represses telomerase activity and
telomerase reverse transcriptase mRNA expression in the cells. Biol
Pharm Bull. 27:1769–1774. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang LH, Yang JY, Yang SN, Li Y, Ping GF,
Hou Y, Cui W, Wang ZZ, Xiao W and Wu CF: Suppression of NF-κB
signaling and P-glycoprotein function by gambogic acid
synergistically potentiates adriamycin-induced apoptosis in lung
cancer. Curr Cancer Drug Targets. 14:91–103. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sharom FJ: Complex interplay between the
P-glycoprotein multidrug efflux pump and the membrane: Its role in
modulating protein function. Front Oncol. 4:412014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bai L, Chen J, McEachern D, Liu L, Zhou H,
Aguilar A and Wang S: BM-1197: A novel and specific Bcl-2/Bcl-xL
inhibitor inducing complete and long-lasting tumor regression in
vivo. PLoS One. 9:e994042014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yamaguchi M: The anti-apoptotic effect of
regucalcin is mediated through multisignaling pathways. Apoptosis.
18:1145–1153. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mai CW, Yaeghoobi M, Abd-Rahman N, Kang YB
and Pichika MR: Chalcones with electron-withdrawing and
electron-donating substituents: Anticancer activity against TRAIL
resistant cancer cells, structure-activity relationship analysis
and regulation of apoptotic proteins. Eur J Med Chem. 77:378–387.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Rohr UP, Wulf MA, Stahn S, Heyd F, Steidl
U, Fenk R, Opalka B, Pitschke G, Prisack HB, Bojar H, et al:
Non-small lung cancer cells are prime targets for p53 gene transfer
mediated by a recombinant adeno-associated virus type-2 vector.
Cancer Gene Ther. 10:898–906. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Cuddihy AR, Jalali F, Coackley C and
Bristow RG: WTp53 induction does not override MTp53 chemoresistance
and radioresistance due to gain-of-function in lung cancer cells.
Mol Cancer Ther. 7:980–992. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Lai SL, Perng RP and Hwang J: p53 gene
status modulates the chemosensitivity of non-small cell lung cancer
cells. J Biomed Sci. 7:64–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Osaki S, Nakanishi Y, Takayama K, Pei XH,
Ueno H and Hara N: Alteration of drug chemosensitivity caused by
the adenovirus-mediated transfer of the wild-type p53 gene in human
lung cancer cells. Cancer Gene Ther. 7:300–307. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Brattström D, Bergqvist M, Lamberg K,
Kraaz W, Scheibenflug L, Gustafsson G, Inganäs M, Wagenius G and
Brodin O: Complete sequence of p53 gene in 20 patients with lung
cancer: Comparison with chemosensitivity and immunohistochemistry.
Med Oncol. 15:255–261. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Blandino G, Levine AJ and Oren M: Mutant
p53 gain of function: Differential effects of different p53 mutants
on resistance of cultured cells to chemotherapy. Oncogene.
18:477–485. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Gu J, Tang Y, Liu Y, Guo H, Wang Y, Cai L,
Li Y and Wang B: Murine double minute 2 siRNA and wild-type p53
gene therapy enhances sensitivity of the SKOV3/DDP ovarian cancer
cell line to cisplatin chemotherapy in vitro and in vivo. Cancer
Lett. 343:200–209. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Levine AJ, Momand J and Finlay CA: The p53
tumour suppressor gene. Nature. 351:453–456. 1991. View Article : Google Scholar : PubMed/NCBI
|
